tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Stock WebsitesTop Gainers/ Losers/ Active StocksDividend StocksChatGPT Stocks
ETFs
ETF CenterTop ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Crypto CenterBitcoin
Popular
Ethereum
Research Tools
Stock ScreenerETF Screener
Popular
Compare StocksCompare ETFsTrending StocksTechnical Analysis ScreenerPenny Stock ScreenerDaily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit CalculatorCompound Interest Calculator
New
Mortgage Calculator
New
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Stock Websites
Top Gainers/ Losers/ Active Stocks
Dividend Stocks
ChatGPT Stocks
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Research Tools
Stock Screener
ETF Screener
Popular
Compare Stocks
Compare ETFs
Trending Stocks
Technical Analysis Screener
Penny Stock Screener
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compound Interest Calculator
New
Mortgage Calculator
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Enterprise Solutions
Plans & Pricing
Education
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us
Magenta Therapeutics Inc (MGTA)
NASDAQ:MGTA
MGTA
Magenta Therapeutics
Stock Analysis
Analyst Forecasts
Technical Analysis
Options
New
Chart
Earnings
Dividends
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

Magenta Therapeutics (MGTA) Stock Forecast & Price Target

247 Followers
See the Price Targets and Ratings of:
See bloggers sentiment and opinion on MGTA
>

MGTA Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Magenta
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MGTA Stock 12 Months Forecast

There Are No Analyst Ratings for MGTA In The Last 3 Months.
Highest Price Target―Average Price Target―Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

MGTA Financial Forecast

MGTA Earnings Forecast

Next quarter’s earnings estimate for MGTA is -$0.80 with a range of -$0.80 to -$0.80. The previous quarter’s EPS was -$0.47. MGTA beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.63% of the time in the same period. In the last calendar year MGTA has Underperformed its overall industry.
Next quarter’s earnings estimate for MGTA is -$0.80 with a range of -$0.80 to -$0.80. The previous quarter’s EPS was -$0.47. MGTA beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.63% of the time in the same period. In the last calendar year MGTA has Underperformed its overall industry.
No data currently available

MGTA Sales Forecast

Next quarter’s sales forecast for MGTA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MGTA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 44.51% of the time in the same period. In the last calendar year MGTA has Underperformed its overall industry.
Next quarter’s sales forecast for MGTA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MGTA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 44.51% of the time in the same period. In the last calendar year MGTA has Underperformed its overall industry.
No data currently available

MGTA Analyst Recommendation Trends

MGTA has not received any ratings in the last 3 months.
MGTA has not received any ratings in the last 3 months.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MGTA
Edward White
H.C. Wainwright
―
Hold
―
Reiterated
Magenta Therapeutics (MGTA) Receives a Hold from H.C. Wainwright
Wedbush Analyst forecast on MGTA
David Nierengarten
Wedbush
$1.00
Hold
42.94%
Upside
Downgraded
Wedbush Downgrades Magenta Therapeutics to Neutral
TD Cowen Analyst forecast on MGTA
Marc Frahm
TD Cowen
―
Hold
―
Downgraded
Cowen Co. Downgrades Magenta Therapeutics to Market Perform
BTIG Analyst forecast on MGTA
Yun Zhong
BTIG
―
Hold
―
Downgraded
Magenta Therapeutics downgraded to Neutral at BTIG after MGTA-117 trial pausedBTIG analyst Yun Zhong downgraded Magenta Therapeutics to Neutral from Buy with no price target after the company announced that the latest participant dosed at the Cohort 3 level in the ongoing MGTA -117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia, or AML, and myelodysplastic syndrome, or MDS, experienced a Grade 5 Serious Adverse Event. Magenta reported the death of the latest patient that received the Cohort 3 dose and the firm worries that the likelihood of an FDA approval for Magenta to evaluate MGTA-117 in transplant-eligible patients "has been significantly reduced" given that MGTA-117s toxicities "appear to be more serious that we expected."
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

MGTA Stock Forecast FAQ

What is MGTA’s average 12-month price target, according to analysts?
Currently, no data Available
What is MGTA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for MGTA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is MGTA a Buy, Sell or Hold?
      Currently, no data Available
      What is Magenta Therapeutics Inc’s price target?
      Currently, no data Available
      What do analysts say about Magenta Therapeutics Inc?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of MGTA?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

        Get More with TipRanks Premium

        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing